Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy

被引：7

作者：

Galli, Giulia ^{[1
]}

Proto, Claudia ^{[1
]}

Signorelli, Diego ^{[1
]}

Imbimbo, Martina ^{[1
]}

Ferrara, Roberto ^{[1
]}

Prelaj, Arsela ^{[1
]}

De Toma, Alessandro ^{[1
]}

Ganzinelli, Monica ^{[1
]}

Zilembo, Nicoletta ^{[1
]}

de Braud, Filippo ^{[1
,2
]}

Garassino, Marina C. ^{[1
]}

Lo Russo, Giuseppe ^{[1
]}

机构：

[1] Fdn IRCCS Ist Nazl Tumori, Unit Thorac Oncol, Dept Med Oncol, Via G Venezian 1, I-20133 Milan, Italy

[2] Univ Milan, Dept Med Oncol & Hematol, Via Festa Perdono 7, I-20122 Milan, Italy

来源：

FUTURE ONCOLOGY | 2019年 / 15卷 / 23期

关键词：

disease response; immunotherapy; long-term benefit; non-small-cell lung cancer; survival; OPEN-LABEL; LIGAND; NIVOLUMAB; DOCETAXEL; SURVIVAL; PEMBROLIZUMAB; CHEMOTHERAPY; MULTICENTER; MONOTHERAPY; INHIBITION;

D O I：

10.2217/fon-2019-0055

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: A minority of patients gains advantage from immunotherapy (IO). Predictive variables of long-term benefit (LTB) are incompletely understood. Materials & methods: We retrospectively collected data about metastatic non-small-cell lung cancer patients treated with IO from April 2013 to July 2017. We defined LTB to IO as complete response (CR), partial response (PR) or disease stability as best response and maintaining it for >= 12 months. Results: Thirty-five of the 147 patients had LTB. More LTB patients than controls showed CR/PR as first and best response to IO. Only CR/PR as best response to IO retained association to LTB at multivariate analyses. Conclusion: Objective response appears as a central factor for LTB from IO.

引用

页码：2743 / 2757

页数：15

共 50 条

[41] FDA Approves Breakthrough Immunotherapy for Patients With Non-Small-Cell Lung Cancer
Printz, Carrie
CANCER, 2017, 123 (02) : 191 - 191
[42] Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
Landi, Lorenza
D'Inca, Federica
Gelibter, Alain
Chiari, Rita
Grossi, Francesco
Delmonte, Angelo
Passaro, Antonio
Signorelli, Diego
Gelsomino, Francesco
Galetta, Domenico
Giannarelli, Diana
Parra, Hector Soto
Minuti, Gabriele
Tiseo, Marcello
Migliorino, Maria Rita
Cognetti, Francesco
Toschi, Luca
Bidoli, Paolo
Piantedosi, Francovito
Calabro, Luana
Cappuzzo, Federico
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01):
[43] Characterization of lung cancer stem/initiating cells from non-small-cell lung cancer patients
Chen, Wan-Jiun
Chen, Huei-Wen
Ho, Chao-Chi
Chen, Hsuan-Yu
Yang, Pan-Chyr
CANCER RESEARCH, 2011, 71
[44] Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary
Dy, Grace K.
Govindan, Ramaswamy
Velcheti, Vamsidhar
Falchook, Gerald S.
Italiano, Antoine
Wolf, Juergen
Sacher, Adrian G.
Takahashi, Toshiaki
Ramalingam, Suresh S.
Dooms, Christophe
Kim, Dong-Wan
Addeo, Alfredo
Desai, Jayesh
Schuler, Martin
Tomasini, Pascale
Hong, David S.
Lito, Piro
Tran, Qui
Jones, Simon
Anderson, Abraham
Hindoyan, Antreas
Snyder, Wendy
Skoulidis, Ferdinandos
Li, Bob T.
FUTURE ONCOLOGY, 2024, 20 (03) : 113 - 120
[45] Basal lymphopenia as a potential predictor of benefit from immunotherapy in metastatic non-small cell lung cancer
Galli, G.
Poggi, M.
Fuca, G.
Lo Russo, G.
Proto, C.
Signorelli, D.
Vitali, M.
Ganzinelli, M.
Zilembo, N.
de Braud, F.
Garassino, M. C.
Imbimbo, M.
ANNALS OF ONCOLOGY, 2018, 29
[46] Predictive Factors Associated with Long-Term Response to Combination Immunotherapy in Patients with Untreated Advanced Non-Small-Cell Lung Cancer: A Multicenter Retrospective Study
Sonehara, Kei
Ozawa, Ryota
Hama, Mineyuki
Nozawa, Shuhei
Agatsuma, Toshihiko
Nishie, Kenichi
Kato, Akane
Matsuo, Akemi
Araki, Taisuke
Komatsu, Masamichi
Tateishi, Kazunari
Hanaoka, Masayuki
ONCOLOGY, 2023, 101 (07) : 425 - 434
[47] New Strategies and Combinations to Improve Outcomes in Immunotherapy in Metastatic Non-Small-Cell Lung Cancer
Corke, Lucy
Sacher, Adrian
CURRENT ONCOLOGY, 2022, 29 (01) : 38 - 55
[48] Clinical Benefit from Docetaxel plus /- Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy
Qin, Kang
Wang, Kaiwen
Li, Shenduo
Hong, Lingzhi
Padmakumar, Priyadharshini
Waree, Rinsurongkawong
Hubert, Shawna M.
Le, Xiuning
Vokes, Natalie
Rai, Kunal
Vaporciyan, Ara
Gibbons, Don L.
Heymach, John V.
Lee, J. Jack
Woodman, Scott E.
Chung, Caroline
Jaffray, David A.
Altan, Mehmet
Lou, Yanyan
Zhang, Jianjun
CANCERS, 2024, 16 (05)
[49] Recent advances in immunotherapy for non-small-cell lung cancer
Suzuki, Hiroyuki
Owada, Yuki
Watanabe, Yuzuru
Inoue, Takuya
Fukuharav, Mitsuro
Yamaura, Takumi
Mutoh, Satoshi
Okabe, Naoyuki
Yaginuma, Hiroshi
Hasegawa, Takeo
Yonechi, Atsushi
Ohsugi, Jun
Hoshino, Mika
Higuchi, Mitsunori
Shio, Yutaka
Gotoh, Mitsukazu
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (02) : 352 - 357
[50] Targeted therapies and immunotherapy in non-small-cell lung cancer
Cortinovis, D.
Abbate, M.
Bidoli, P.
Capici, S.
Canova, S.
ECANCERMEDICALSCIENCE, 2016, 10

← 1 2 3 4 5 →